Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Τετάρτη 19 Απριλίου 2017

Revision of sleeve gastrectomy to Roux-en-Y Gastric Bypass: A Canadian experience.

Related Articles

Revision of sleeve gastrectomy to Roux-en-Y Gastric Bypass: A Canadian experience.

Am J Surg. 2017 Apr 08;:

Authors: Yorke E, Sheppard C, Switzer NJ, Kim D, de Gara C, Karmali S, Kanji A, Birch D

Abstract
INTRODUCTION: Sleeve gastrectomy (SG) can be associated with inadequate weight loss, insufficient resolution of co-morbidities and severe reflux. Conversion to Roux-en-Y Gastric Bypass (RYGB) is a potential solution. The aim of this study was to determine the common indications for conversion from SG to RYGB at our centre, and evaluate patient outcomes with respect to weight loss and co-morbidity resolution.
METHODS: A retrospective review of patients who underwent conversion from SG to RYGB between 2008 and 2015.
RESULTS: 273 SGs were performed of which 6.6% (n = 18) were converted to RYGB most commonly due to inadequate weight loss (65.3%) and severe reflux (26.1%). Two patients were converted as a planned two-stage approach to RYGB. Patients went from a mean preoperative BMI of 50.5 to a mean BMI of 40.5 post-SG on average by 20.9 months. The mean time to conversion was 41.8 months. There was a positive correlation between pre-SG BMI and time to conversion (p = 0.040). The mean BMI after conversion was 36.4, but this additional weight loss was not significant (p = 0.057). After conversion, four of the five diabetic patients are now medication free and 75% of patients no longer have reflux symptoms. All patients had complete resolution of their hypertension and obstructive sleep apnea. Revision perioperative complication rates were comparable to primary RYGB. Two patients developed new onset iron deficiency anemia.
CONCLUSION: Revision to RYGB is a safe option for SG failure and resulted in significant benefits from co-morbidity resolution.

PMID: 28416180 [PubMed - as supplied by publisher]



http://ift.tt/2oUSydv

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου